H. Lundbeck A/S- to Post FY2021 Earnings of $2.99 Per Share, Jefferies Group Forecasts (HLUYY)

H. Lundbeck A/S- (OTCMKTS:HLUYY) – Jefferies Group cut their FY2021 EPS estimates for H. Lundbeck A/S- in a research report issued on Thursday. Jefferies Group analyst P. Welford now anticipates that the company will post earnings of $2.99 per share for the year, down from their prior estimate of $3.80.

Separately, Zacks Investment Research downgraded H. Lundbeck A/S- from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th.

Shares of H. Lundbeck A/S- (HLUYY) opened at $49.98 on Monday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.13 and a current ratio of 1.36. The company has a market capitalization of $9,947.41, a P/E ratio of 20.82, a price-to-earnings-growth ratio of 3.12 and a beta of 0.09. H. Lundbeck A/S- has a one year low of $40.70 and a one year high of $66.67.

COPYRIGHT VIOLATION NOTICE: “H. Lundbeck A/S- to Post FY2021 Earnings of $2.99 Per Share, Jefferies Group Forecasts (HLUYY)” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/12/h-lundbeck-a-s-to-post-fy2021-earnings-of-2-99-per-share-jefferies-group-forecasts-hluyy.html.

About H. Lundbeck A/S-

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply